FDA Nano Meeting Is Just The Beginning of Supplement, OTC Questions
This article was originally published in The Tan Sheet
Executive Summary
Rather than draft a potentially "onerous rule" based on insufficient current information about the use of nanotechnology in dietary supplements, OTC drugs and other products, FDA needs additional safety data to determine if guidance is even necessary, a leading industry scientist says